Brief psychotic disorder associated with quarantine and mild COVID-19. Issue 12 (16th December 2020)

• Record Type: Journal Article
• Authors: Haddad, Peter M; Al Abdulla, Majid; Latoo, Javed; Iqbal, Yousaf
• Is Part Of: BMJ case reports. Volume 13:Issue 12(2020)
• Publication Date: 2020-12-16
• Subjects: psychotic disorders (incl schizophrenia) -- psychiatry (drugs and medicines) -- COVID-19; Medicine -- Case studies -- Periodicals; 610.5
• DOI: 10.1136/bcr-2020-240088
• Languages: English
• ISSNs: 1757-790X

Abstract

Abstract : A 30-year-old man with no significant previous or family psychiatric history became severely anxious about his health after a positive COVID-19 test. Physical symptoms of COVID-19 were mild, with no evidence of hypoxia or pneumonia, throughout his illness. He was admitted to a quarantine facility. He remained highly anxious, and 1 week later, he developed paranoid delusions and auditory hallucinations (his first psychotic episode). He was treated with lorazepam 1 mg four times a day, mirtazapine 30 mg nocte and risperidone 1 mg two times a day. His psychotic symptoms lasted 1 week. He stopped psychiatric medication after 4 weeks and had remained well when reviewed 3 months later. A Diagnostic and Statistical Manual of Mental Disorders fifth edition diagnosis of brief psychotic disorder with marked stressor (brief reactive psychosis) was made. Anxiety about his health and social isolation appeared the main aetiological factors but an inflammatory component cannot be excluded. The case highlights that first episode psychosis can be associated with mild COVID-19.